Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 204 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bacterial Pneumonia Clear all
Terminated Phase 4 Interventional Results available

BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia

NCT05102162
View directory record Official record
Conditions
Pneumonia
Interventions
Cefepime, Meropenem, or Piperacillin/Tazobactam
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

NCT02559310
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 7, 2026, 11:34 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

NCT01198626
View directory record Official record
Conditions
Community-Acquired Bacterial Pneumonia (CABP)
Interventions
JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Phase 4 Interventional Results available

Rapid Empiric Treatment With Oseltamivir Study (RETOS)

NCT01248715
View directory record Official record
Conditions
Influenza, Pneumonia
Interventions
oseltamivir
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
1,107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

NCT04168190
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, Pneumovax™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
20
States / cities
Birmingham, Alabama • Mesa, Arizona • Coral Gables, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 7, 2026, 11:34 AM EDT
Active, not recruiting Not applicable Interventional

Discharge Stewardship in Children's Hospitals

NCT05826873
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumonia Childhood, Urinary Tract Infections, Soft Tissue Infections, Skin Infections, Community-acquired Pneumonia
Interventions
Discharge antibiotic stewardship intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
28 Days to 18 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Phase 3 Interventional

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides

NCT00000802
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone, Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 7, 2026, 11:34 AM EDT
Terminated Phase 1 Interventional Results available

Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia

NCT03862040
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Cefiderocol, Standard of Care Antibiotic
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
7
States / cities
Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 7, 2026, 11:34 AM EDT
Completed No phase listed Observational

Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center

NCT00870857
View directory record Official record
Conditions
HIV Infections, Emphysema, Chronic Obstructive Pulmonary Disease, Pneumocystis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Not applicable Interventional

A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

NCT00002283
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimethoprim, Sulfamethoxazole, Dapsone
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Not applicable Interventional

Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections

NCT02292498
View directory record Official record
Conditions
Infections, Bacterial, Pneumonia, Bacterial
Interventions
FLIR ONE
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Not applicable Interventional

A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.

NCT00002102
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Leucovorin calcium
Drug
Lead sponsor
U.S. Bioscience
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
West Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Not applicable Interventional

Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy

NCT00000722
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 7, 2026, 11:34 AM EDT
Recruiting No phase listed Observational

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

NCT06746883
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions
Non-interventional
Other
Lead sponsor
Innoviva Specialty Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Sacramento, California • Gainesville, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)

NCT01589185
View directory record Official record
Conditions
Pneumonia Due to Staphylococcus Aureus
Interventions
KBSA301, Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 7, 2026, 11:34 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 7, 2026, 11:34 AM EDT
Completed No phase listed Observational

Risks of Bacterial and Fungal Superinfection in Patients With COVID-19

NCT05256316
View directory record Official record
Conditions
COVID-19
Interventions
Previously admitted COVID-19 patients in intensive care units
Other
Lead sponsor
The University of Queensland
Other
Eligibility
18 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 7, 2026, 11:34 AM EDT
Completed No phase listed Observational

New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia

NCT00342589
View directory record Official record
Conditions
Pneumocystis Infection, Infection, Pneumonia, Pneumocystis, Lung Disease, Fungal, Mycoses
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Phase 3 Interventional

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT04368559
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions
Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Phase 3 Interventional

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

NCT00035269
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
Interventions
Antibiotic
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
34
States / cities
Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

NCT00021567
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection
Interventions
Interferon Gamma for Aerosol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 7, 2026, 11:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure

NCT05799976
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Diabetes Mellitus, Breast Cancer, Colorectal Cancer
Interventions
Text message nudge
Behavioral
Lead sponsor
Mitesh Patel
Industry
Eligibility
18 Years and older
Enrollment
29,334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 7, 2026, 11:34 AM EDT
Completed No phase listed Observational

Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia

NCT01086397
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Interventions
Urine sample collection
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Mobile, Alabama • La Mesa, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 7, 2026, 11:34 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

NCT02663674
View directory record Official record
Conditions
Coccidioidomycosis
Interventions
Fluconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 7, 2026, 11:34 AM EDT